NCT04802161View on ClinicalTrials.gov

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

November 21, 2024

Study Completion Date

April 25, 2026

Conditions
Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia With Multilineage DysplasiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyeloproliferative Neoplasm
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspirate and biopsy

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

DRUG

Pomalidomide

Given PO

Trial Locations (11)

10065

NYP/Weill Cornell Medical Center, New York

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

22908

University of Virginia Cancer Center, Charlottesville

27157

Wake Forest University Health Sciences, Winston-Salem

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

43210

Ohio State University Comprehensive Cancer Center, Columbus

45069

University of Cincinnati Cancer Center-West Chester, West Chester

45219

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati

66160

University of Kansas Cancer Center, Kansas City

66205

University of Kansas Hospital-Westwood Cancer Center, Westwood

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH